“Expanded 2026 ADA Guidance on SGLT2i in CKD Starting at eGFR ≥20 and combining with a nonsteroidal MRA” (2026) Diabzen, 4(17), pp. 34–35. Available at: https://www.thediabzen.com/index.php/d/article/view/60 (Accessed: 17 September 2026).